The North America Musculoskeletal Disorders Drugs Market would witness market growth of 3.0% CAGR during the forecast period (2023-2029).
Musculoskeletal disorders (MSDs) are injuries and conditions that affect the human body's musculoskeletal system, which consists of bones, discs, tendons, ligaments, muscles, nerves, and blood vessels, and are also responsible for the body's movement. MSDs can affect numerous body regions, including the neck, upper and lower back, shoulders, and extremities, including the arms, legs, hands, and feet.
Manifestations of these disorders include pain, weakness, rigidity, swelling, and restricted range of motion. In addition, musculoskeletal disorders are characterized by swelling, stiff joints, dull pains, and recurrent pain. Medications include corticosteroids, analgesics, and disease-modifying anti-rheumatic medicines (DMARDs). These medications treat inflammation, pain, and other symptoms related to these conditions in various ways.
Over 4.2 million Canadians (16%) aged 15 or older reported having arthritis in 2007-08. By 2031, this figure will rise to almost 7 million (20%) due to the aging population. Although arthritis is more common in older people, it affects people of all ages, including those who are in the prime of their life. Although there is no known cure for arthritis, advances in the knowledge of the many disorders continue to produce improved drugs and therapies for the condition. Hence, the demand for medications to treat musculoskeletal problems will surge as the prevalence of arthritis rises in the region, boosting market expansion in North America.
The US market dominated the North America Musculoskeletal Disorders Drugs Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $28,248 Million by 2029. The Canada market is exhibiting a CAGR of 5% during (2023 - 2029). Additionally, The Mexico market would experience a CAGR of 4.7% during (2023 - 2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Drug Type, the market is segmented into Analgesics, DMARDs, Corticosteroids and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Musculoskeletal Disorders Drugs Market is Projected to reach USD 109.4 Billion by 2029, at a CAGR of 4.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Route of Administration
By Drug Type
- Analgesics
- DMARDs
- Corticosteroids
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- AbbVie, Inc.
- Amgen, Inc.
- Eli Lilly And Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Musculoskeletal Disorders Drugs Market, by Distribution Channel
1.4.2 North America Musculoskeletal Disorders Drugs Market, by Route of Administration
1.4.3 North America Musculoskeletal Disorders Drugs Market, by Drug Type
1.4.4 North America Musculoskeletal Disorders Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Geographical Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. North America Musculoskeletal Disorders Drugs Market by Distribution Channel
4.1 North America Drug Stores & Retail Pharmacies Market by Country
4.2 North America Hospital Pharmacies Market by Country
4.3 North America Online Providers Market by Country
Chapter 5. North America Musculoskeletal Disorders Drugs Market by Route of Administration
5.1 North America Parenteral Market by Country
5.2 North America Oral Market by Country
Chapter 6. North America Musculoskeletal Disorders Drugs Market by Drug Type
6.1 North America Analgesics Market by Country
6.2 North America DMARDs Market by Country
6.3 North America Corticosteroids Market by Country
6.4 North America Others Market by Country
Chapter 7. North America Musculoskeletal Disorders Drugs Market by Country
7.1 US Musculoskeletal Disorders Drugs Market
7.1.1 US Musculoskeletal Disorders Drugs Market by Distribution Channel
7.1.2 US Musculoskeletal Disorders Drugs Market by Route of Administration
7.1.3 US Musculoskeletal Disorders Drugs Market by Drug Type
7.2 Canada Musculoskeletal Disorders Drugs Market
7.2.1 Canada Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.2 Canada Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.3 Canada Musculoskeletal Disorders Drugs Market by Drug Type
7.3 Mexico Musculoskeletal Disorders Drugs Market
7.3.1 Mexico Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.2 Mexico Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.3 Mexico Musculoskeletal Disorders Drugs Market by Drug Type
7.4 Rest of North America Musculoskeletal Disorders Drugs Market
7.4.1 Rest of North America Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.2 Rest of North America Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.3 Rest of North America Musculoskeletal Disorders Drugs Market by Drug Type
Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.6 SWOT Analysis
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Approvals and Trials:
8.3.5.2 Acquisition and Mergers:
8.3.5.3 Geographical Expansions:
8.4 UCB S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Acquisition and Mergers:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.6 Eli Lilly And Company
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.7 F. Hoffmann-La Roche Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.8 Merck & Co., Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.9 Novartis AG
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Teva Pharmaceutical Industries Ltd.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
TABLE 1 North America Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 2 North America Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Musculoskeletal Disorders Drugs Market
TABLE 4 geographical expansions – Musculoskeletal Disorders Drugs Market
TABLE 5 Acquisition and Mergers– Musculoskeletal Disorders Drugs Market
TABLE 6 Approvals and trials – Musculoskeletal Disorders Drugs Market
TABLE 7 North America Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 North America Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 9 North America Drug Stores & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Drug Stores & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 11 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 13 North America Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Online Providers Market by Country, 2023 - 2029, USD Million
TABLE 15 North America Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 16 North America Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 17 North America Parenteral Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Parenteral Market by Country, 2023 - 2029, USD Million
TABLE 19 North America Oral Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Oral Market by Country, 2023 - 2029, USD Million
TABLE 21 North America Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 22 North America Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 23 North America Analgesics Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Analgesics Market by Country, 2023 - 2029, USD Million
TABLE 25 North America DMARDs Market by Country, 2019 - 2022, USD Million
TABLE 26 North America DMARDs Market by Country, 2023 - 2029, USD Million
TABLE 27 North America Corticosteroids Market by Country, 2019 - 2022, USD Million
TABLE 28 North America Corticosteroids Market by Country, 2023 - 2029, USD Million
TABLE 29 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 31 North America Musculoskeletal Disorders Drugs Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Musculoskeletal Disorders Drugs Market by Country, 2023 - 2029, USD Million
TABLE 33 US Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 34 US Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 35 US Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 36 US Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 37 US Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 38 US Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 39 US Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 40 US Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 41 Canada Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 42 Canada Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 43 Canada Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 44 Canada Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 45 Canada Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 46 Canada Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 47 Canada Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 48 Canada Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 49 Mexico Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 50 Mexico Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 51 Mexico Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 52 Mexico Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 53 Mexico Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 54 Mexico Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 55 Mexico Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 56 Mexico Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 57 Rest of North America Musculoskeletal Disorders Drugs Market, 2019 - 2022, USD Million
TABLE 58 Rest of North America Musculoskeletal Disorders Drugs Market, 2023 - 2029, USD Million
TABLE 59 Rest of North America Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 60 Rest of North America Musculoskeletal Disorders Drugs Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 61 Rest of North America Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2022, USD Million
TABLE 62 Rest of North America Musculoskeletal Disorders Drugs Market by Route of Administration, 2023 - 2029, USD Million
TABLE 63 Rest of North America Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2022, USD Million
TABLE 64 Rest of North America Musculoskeletal Disorders Drugs Market by Drug Type, 2023 - 2029, USD Million
TABLE 65 Key information –Johnson & Johnson
TABLE 66 Key Information – Pfizer, Inc.
TABLE 67 Key information – AbbVie, Inc.
TABLE 68 Key Information – UCB S.A.
TABLE 69 Key Information – Amgen, Inc.
TABLE 70 Key Information – Eli Lilly And Company
TABLE 71 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 72 KEY INFORMATION - Merck & Co., Inc.
TABLE 73 Key Information – Novartis AG
TABLE 74 Key Information – Teva Pharmaceuticals Industries Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 North America Musculoskeletal Disorders Drugs Market Share by Distribution Channel, 2022
FIG 5 North America Musculoskeletal Disorders Drugs Market Share by Distribution Channel, 2029
FIG 6 North America Musculoskeletal Disorders Drugs Market by Distribution Channel, 2019 - 2029, USD Million
FIG 7 North America Musculoskeletal Disorders Drugs Market Share by Route of Administration, 2022
FIG 8 North America Musculoskeletal Disorders Drugs Market Share by Route of Administration, 2029
FIG 9 North America Musculoskeletal Disorders Drugs Market by Route of Administration, 2019 - 2029, USD Million
FIG 10 North America Musculoskeletal Disorders Drugs Market Share by Drug Type, 2022
FIG 11 North America Musculoskeletal Disorders Drugs Market Share by Drug Type, 2029
FIG 12 North America Musculoskeletal Disorders Drugs Market by Drug Type, 2019 - 2029, USD Million
FIG 13 North America Musculoskeletal Disorders Drugs Market Share by Country, 2022
FIG 14 North America Musculoskeletal Disorders Drugs Market Share by Country, 2029
FIG 15 North America Musculoskeletal Disorders Drugs Market by Country, 2019 - 2029, USD Million
FIG 16 SWOT analysis: Johnson & Johnson
FIG 17 Recent strategies and developments: Pfizer, Inc.
FIG 18 Recent strategies and developments: AbbVie, Inc.